{"entity":{"id":"nct05990452","kind":"trial","name":"Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of 9MW2921 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., active and no longer recruiting.","summary":"Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05990452 by Mabwell (Shanghai) Bioscience Co., Ltd., with 261 participants enrolled, started 2023-08-28 and due to reach its primary completion in 2026-09-01. Interventions recorded: 9MW2921.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05990452","url":"https://clinicaltrials.gov/study/NCT05990452"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05990452","phase":"1/2","setting":"A Phase I/II First-in-human Study of 9MW2921 to Evaluate the Safety, Tolerability and Preliminary Efficacy of 9MW2921 in Patients With Advanced Solid Tumors","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","enrolled":261,"outcomes":[]},"route":"/trials/nct05990452/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}